StockData
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc (BMRN) stock

BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$58.51+0.52 (+0.90%)

Close on Nov 17, 2026Market cap $11.33BP/E 154.0Yield –

BioMarin Pharmaceutical operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

BioMarin Pharmaceutical's operating cash flow for the twelve months ending Jun 30, 2026 was $857.09M, up 11.8% year over year. For fiscal 2025 it was $827.99M, up 44.5% from the year before. The highest annual figure on record is $827.99M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$827.99M+44.5%
FY2024Dec 31, 2024$572.84M+259.7%
FY2023Dec 31, 2023$159.26M-9.5%
FY2022Dec 31, 2022$175.90M-42.2%
FY2021Dec 31, 2021$304.54M+256.7%
FY2020Dec 31, 2020$85.37M+76.9%
FY2019Dec 31, 2019$48.26M+138.8%
FY2018Dec 31, 2018$20.21M–
FY2017Dec 31, 2017-$8.76M–
FY2016Dec 31, 2016-$227.84M–
FY2015Dec 31, 2015-$219.50M–
FY2014Dec 31, 2014-$70.42M–
FY2013Dec 31, 2013-$57.34M-425.6%
FY2012Dec 31, 2012$17.61M-4.4%
FY2011Dec 31, 2011$18.42M-1.8%
FY2010Dec 31, 2010$18.75M-78.6%
FY2009Dec 31, 2009$87.73M–
FY2008Dec 31, 2008-$9.18M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$168.11M-9.3%
Q1 FY2026Mar 31, 2026$220.65M+26.5%
Q4 FY2025Dec 31, 2025$99.64M-46.3%
Q3 FY2025Sep 30, 2025$368.69M+66.5%
Q2 FY2025Jun 30, 2025$185.27M+56.0%
Q1 FY2025Mar 31, 2025$174.39M+271.3%
Q4 FY2024Dec 31, 2024$185.63M+575.4%
Q3 FY2024Sep 30, 2024$221.48M+63.3%
Q2 FY2024Jun 30, 2024$118.76M+69.5%
Q1 FY2024Mar 31, 2024$46.97M–
Q4 FY2023Dec 31, 2023$27.48M+305.0%
Q3 FY2023Sep 30, 2023$135.65M-14.3%
Q2 FY2023Jun 30, 2023$70.06M+24.6%
Q1 FY2023Mar 31, 2023-$73.93M–
Q4 FY2022Dec 31, 2022$6.79M-39.3%
Q3 FY2022Sep 30, 2022$158.32M+63.1%
Q2 FY2022Jun 30, 2022$56.23M-32.1%
Q1 FY2022Mar 31, 2022-$45.43M-140.0%
Q4 FY2021Dec 31, 2021$11.18M–
Q3 FY2021Sep 30, 2021$97.06M+12.6%
Q2 FY2021Jun 30, 2021$82.78M+198.5%
Q1 FY2021Mar 31, 2021$113.51M–
Q4 FY2020Dec 31, 2020-$13.38M-123.3%
Q3 FY2020Sep 30, 2020$86.21M+22.9%
Q2 FY2020Jun 30, 2020$27.74M–
Q1 FY2020Mar 31, 2020-$15.19M–
Q4 FY2019Dec 31, 2019$57.34M+16.1%
Q3 FY2019Sep 30, 2019$70.13M+48.6%
Q2 FY2019Jun 30, 2019-$24.34M–
Q1 FY2019Mar 31, 2019-$54.87M–
Q4 FY2018Dec 31, 2018$49.37M+237.9%
Q3 FY2018Sep 30, 2018$47.20M+23.3%
Q2 FY2018Jun 30, 2018-$33.86M-280.3%
Q1 FY2018Mar 31, 2018-$42.51M–
Q4 FY2017Dec 31, 2017$14.61M–
Q3 FY2017Sep 30, 2017$38.29M–
Q2 FY2017Jun 30, 2017$18.78M–
Q1 FY2017Mar 31, 2017-$80.44M–
Q4 FY2016Dec 31, 2016-$210.00K–
Q3 FY2016Sep 30, 2016-$10.37M–

More BioMarin Pharmaceutical figures

See a number that looks wrong?